DK0980252T3 - Terapier til akut nyresvigt - Google Patents

Terapier til akut nyresvigt

Info

Publication number
DK0980252T3
DK0980252T3 DK98919715T DK98919715T DK0980252T3 DK 0980252 T3 DK0980252 T3 DK 0980252T3 DK 98919715 T DK98919715 T DK 98919715T DK 98919715 T DK98919715 T DK 98919715T DK 0980252 T3 DK0980252 T3 DK 0980252T3
Authority
DK
Denmark
Prior art keywords
renal failure
acute renal
therapies
risk
treatment
Prior art date
Application number
DK98919715T
Other languages
Danish (da)
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0980252T3 publication Critical patent/DK0980252T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98919715T 1997-05-05 1998-05-05 Terapier til akut nyresvigt DK0980252T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4561997P 1997-05-05 1997-05-05
PCT/US1998/003197 WO1998050060A1 (fr) 1997-05-05 1998-05-05 Therapies contre l'insuffisance renale aigue
EP98919715A EP0980252B1 (fr) 1997-05-05 1998-05-05 Therapies contre l'insuffisance renale aigue

Publications (1)

Publication Number Publication Date
DK0980252T3 true DK0980252T3 (da) 2005-01-31

Family

ID=21938961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98919715T DK0980252T3 (da) 1997-05-05 1998-05-05 Terapier til akut nyresvigt

Country Status (11)

Country Link
US (2) US20100105621A1 (fr)
EP (1) EP0980252B1 (fr)
JP (2) JP5033276B2 (fr)
AT (1) ATE278414T1 (fr)
AU (1) AU743510B2 (fr)
CA (1) CA2289123A1 (fr)
DE (1) DE69826854T2 (fr)
DK (1) DK0980252T3 (fr)
ES (1) ES2226125T3 (fr)
PT (1) PT980252E (fr)
WO (1) WO1998050060A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143078D1 (de) * 2000-01-31 2010-10-28 Uwe Waldemar Rothenpieler Pax2 zur behandlung von nierenkrankheiten
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
EP1407770B1 (fr) 2001-06-26 2013-06-05 Takeda Pharmaceutical Company Limited Promoteur de production/secretion de la superfamille des tgf-beta
JP2006516020A (ja) * 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
WO2007056614A1 (fr) * 2005-11-14 2007-05-18 Merial Limited Thérapie génique pour insuffisance rénale
EP2574625B1 (fr) * 2006-07-21 2015-02-25 HuBit genomix, Inc. Médicament agissant contre une maladie rénale
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
SG11201606514SA (en) 2014-02-07 2016-09-29 Toru Miyazaki Preventive or therapeutic agent for kidney disease
FR3071065B1 (fr) 2017-09-08 2020-10-02 Dcns Dispositif de controle d'isolement et/ou de continuite d'au moins un cable electrique et procede de controle associe

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
ATE162223T1 (de) 1989-03-28 1998-01-15 Genetics Inst Osteoinduktive zusammensetzungen
CA2082941A1 (fr) 1990-05-16 1991-11-17 Rodney M. Hewick Proteines participant a l'induction d'os et de cartilage
JPH0426624A (ja) 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
EP0533840B1 (fr) 1990-06-22 1996-12-11 E.I. Du Pont De Nemours And Company Traitement de l'insuffisance renale chronique a l'aide d'imidazoles antagonistes des recepteurs d'angiotensine-ii
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
CA2363965C (fr) * 1991-03-11 2010-05-18 Curis, Inc. Morphogenese induite par des proteines
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0601129B1 (fr) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Procede de triage de proteines morphogeniques
ATE308336T1 (de) * 1991-08-30 2005-11-15 Curis Inc Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE192931T1 (de) * 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
JP4344012B2 (ja) * 1992-07-31 2009-10-14 ストライカー・コーポレーション 組織形成因子誘導による神経の再生と修復
WO1994003075A2 (fr) 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Composition alimentaire enrichie avec un agent morphogene
WO1994003600A1 (fr) 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Complexe soluble de proteines morphogeniques et sa composition
WO1994006449A2 (fr) 1992-09-16 1994-03-31 Creative Biomolecules, Inc. Regeneration du foie induite par des morphogenes
AU681362B2 (en) 1992-11-03 1997-08-28 Stryker Corporation OP-3-induced morphogenesis
CA2157387C (fr) 1993-03-04 1998-12-15 David C. Rueger Methode et compositions pour la production de proteines osteogeniques recombinantes
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
CA2176709A1 (fr) * 1993-11-15 1995-05-26 Howard R. Higley Procede de traitment d'affections renales par administration de facteur de croissance insulinoide-i (igf-i) et de proteine-3 fixatrice du facteur de croissance insulinoide (igfbp-3)
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
EP0894004B2 (fr) * 1996-03-22 2007-02-21 Curis, Inc. Procede pour favoriser la recuperation fonctionnelle de la coordination motrice, de la parole ou de la perception sensorielle a la suite d'une ischemie ou d'un traumatisme du systeme nerveux central
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
PT980252E (pt) 2005-01-31
AU743510B2 (en) 2002-01-24
US20110257093A1 (en) 2011-10-20
JP2001523264A (ja) 2001-11-20
ATE278414T1 (de) 2004-10-15
EP0980252A1 (fr) 2000-02-23
WO1998050060A1 (fr) 1998-11-12
AU7244398A (en) 1998-11-27
DE69826854T2 (de) 2006-02-02
JP5033276B2 (ja) 2012-09-26
EP0980252B1 (fr) 2004-10-06
JP2009286802A (ja) 2009-12-10
US8748378B2 (en) 2014-06-10
US20100105621A1 (en) 2010-04-29
CA2289123A1 (fr) 1998-11-12
DE69826854D1 (de) 2004-11-11
ES2226125T3 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
ATE277629T1 (de) Morphogenische behandlung des chronischen nierenversagens
DK0980252T3 (da) Terapier til akut nyresvigt
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
DK1238658T3 (da) Understöttet afgivelse af et aktivt middel under anvendelse af et implanterbart system
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
DK0429570T3 (da) Osteoinducerende præparater
NO982436D0 (no) Apparat for oppvarming av blod
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
Dawson et al. The periosteal requirement and temporal dynamics of BMP2‐induced middle phalanx regeneration in the adult mouse
NO865068D0 (no) System, fremgangsmaate og apparat til fraksjonering av blod in situ.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69228997T2 (de) Menschliche il-3-varianten
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
BR9709900A (pt) Proteìnas de ligacão de proteìnas de prìons e usos das mesmas.
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
TR199900596T2 (xx) Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
FR2764389B1 (fr) Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
DK1214091T3 (da) Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
Liu et al. Cell saver filtering of extravasated rhBMP-2 after degenerative scoliosis reconstruction
ATE232738T1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung